Article Versions Notes

Gonzalez-Alvarez I, Ruiz-Picazo A, Selles-Talavera R, Figueroa-Campos A, Merino V, Bermejo M, Gonzalez-Alvarez M. In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug. Pharmaceutics. 2024; 16(3):390. https://doi.org/10.3390/pharmaceutics16030390

Gonzalez-Alvarez, Isabel, Alejandro Ruiz-Picazo, Ruben Selles-Talavera, Andres Figueroa-Campos, Virginia Merino, Marival Bermejo, and Marta Gonzalez-Alvarez. 2024. "In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug" Pharmaceutics 16, no. 3: 390. https://doi.org/10.3390/pharmaceutics16030390

Gonzalez-Alvarez, I., Ruiz-Picazo, A., Selles-Talavera, R., Figueroa-Campos, A., Merino, V., Bermejo, M., & Gonzalez-Alvarez, M. (2024). In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug. Pharmaceutics, 16(3), 390. https://doi.org/10.3390/pharmaceutics16030390